ライフサイエンスコーパス: lactulose

1 ity despite standard of care (SOC; rifaximin/lactulose).

2 ts with MHE, it was not as cost-effective as lactulose.

3 She was intubated, ventilated, and placed on lactulose.

4 n were then measured for 3 h after 20 g oral lactulose.

5 ported with both fiber preparations and with lactulose.

6 retion studies after oral (13)C-mannitol and lactulose.

7 d may further change after administration of lactulose.

8 um for the enzymatic generation of prebiotic lactulose.

9 between specimens collected before and after lactulose.

10 nd converted approximately 17% of lactose to lactulose.

11 1.9 (95 % Crl 0.2, 3.6) respectively versus lactulose.

12 xtracellular glutamate that was prevented by lactulose.

13 native beta-lactoglobulin was 69-2831 mg/L, lactulose 0-824 mg/L and furosine 3.3-68.8 mg/L.

14 8.9 +/- 4.4 and 8.9 +/- 3.9, respectively), lactulose (0.31 +/- 0.20 and 0.33 +/- 0.23, respectively

15 An oral test solution containing 5 g of lactulose, 1 g of L-rhamnose, 0.5 g of D-xylose, and 0.2

16 ) x min(-1)) is two times lower than that of lactulose (13.39 M(-1) x min(-1)).

17 fructose (16.92%), D-tagatose (10.54%), and lactulose (3.62%).

18 harides were lactose, methyl beta-lactoside, lactulose, 4-O-beta-D-galactopyranosyl-D-mannopyranoside

19 Galbeta1,4Fru (lactulose), a natural sugar, was furthermore found to be

20 supplemented with either a placebo (10 g of lactulose, a nonabsorbable sugar), psyllium (a fermentab

21 As proof of principle, supplementation with lactulose, a nonabsorbed simple carbohydrate and an FDA-

22 clofenac, 0.2% glyceryl-trinitrate ointment, lactulose, a telephone number to call for queries in eme

23 Lactulose absorption (0.016-0.039 mmol.h-1.cm-1) was obs

24 ose and that the presence of glucose induced lactulose absorption and enhanced fructose absorption.

25 urve was used to calculate the purity of the lactulose (according to Van't Hoff equation), which was

26 Lactulose administration did not lead to any change in a

27 21 patients provided another specimen after lactulose administration for 55 [42-77] days.

28 healthy persons and do not change following lactulose administration.

29 h cirrhosis and assessed the effect on it of lactulose administration.

30 Despite normal mental status on lactulose after OHE, cirrhotic patients were cognitively

31 ted that of SIBO as 49% (95% CI 40-57%) with lactulose and 19% (95% CI 13-27%) with glucose.

32 eration and absorption in the colon by using lactulose and a reduced protein diet.

33 dard treatment for hepatic encephalopathy is lactulose and alteration of gut flora.

34 Our studies suggest that lactulose and bifidobacteria serve as a synbiotic to red

35 arried out after intraluminal injection of H lactulose and C mannitol in the ileum of sham, B, EF, an

36 E, intravenous LOLA (as an add-on therapy to lactulose and ceftriaxone) significantly improves the gr

37 Standard of care treatment (including lactulose and ceftriaxone) was given in both groups.

38 However, lactulose and certain fructose-containing compounds, cal

39 Therapy with lactulose and enteral antibiotics is appropriate in any

40 hronic constipation were macrogol, fiber and lactulose and for acute constipation sodium picosulfate,

41 onstituted SMPs contained high quantities of lactulose and furosine, the ratio of which was lower tha

42 ns to conjugate with sugars such as lactose, lactulose and galactose.

43 ic review evaluates the effects of the NADs, lactulose and lactitol, for the treatment and prevention

44 no differences in the efficacy or safety of lactulose and lactitol.

45 s a source of several derivatives, including lactulose and lactobionic acid.

46 ng from commercially available disaccharides-lactulose and lactose.

47 At 3 months, all interventions reduced lactulose and mannitol (-0.60 to -0.69 log mmol/L).

48 eability (fecal alpha-1 antitrypsin; urinary lactulose and mannitol assessed through the dual sugar a

49 nd colonic transit, mucosal permeability (by lactulose and mannitol excretion), and cytokine producti

50 rkers of biomedical relevance such as sugars lactulose and mannitol for noninvasive gut permeability

51 ocol to WRA with normal BMI, in whom urinary lactulose and mannitol recovery and the lactulose/mannit

52 leal IAA digestibility of goat milk protein, lactulose and mannitol recovery, LMR, allo-isoleucine an

53 e, and regenerating gene 1B protein; urinary lactulose and mannitol; and plasma kynurenine, tryptopha

54 ducts, which is sustained by the increase in lactulose and protein carbonyl content.

55 nd MB-301 to urinary ratios of sugar tracers lactulose and rhamnose.

56 ent medical treatment predominantly involves lactulose and rifaximin following rigorous treatment of

57 e and rifaximin was more effective than only lactulose and rifaximin in improving grades of HE, recov

58 Combination of LOLA with lactulose and rifaximin was more effective than only lac

59 ting events and pharmacologic treatment with lactulose and rifaximin.

60 le defect and initiation of a treatment with lactulose and the two ammonia scavenger drugs sodium ben

61 mutations in mgl are adaptations specific to lactulose and to methyl-galactoside, respectively.

62 Ninety-one patients drank a lactulose and water mixture (Group 1), and 54 patients d

63 fficed to discriminate between sugars (e.g., lactulose) and sugar alcohols (e.g., mannitol), establis

64 Treatment options include dietary fiber, lactulose, and polyethylene glycol-based laxatives.

65 ides, inulin, galactooligosaccharides (GOS), lactulose, and raffinose was determined by cultural enum

66 ts were randomized to a combination of LOLA, lactulose, and rifaximin (n = 70) or placebo, lactulose,

67 actulose, and rifaximin (n = 70) or placebo, lactulose, and rifaximin (n = 70).

68 nistered dose) for (13)C-mannitol, rhamnose, lactulose, and sucralose were ~30%, ~15%, 0.32%, and 2.3

69 sion of glucose into fructose and lactose to lactulose are demonstrated.

70 on; 3 subjects withdrew from the crystalline lactulose arm (1 before medication initiation, 1 due to

71 For quantitation of lactulose as a model biomarker, we have designed gold na

72 the feces of a healthy infant and identified lactulose as a prebiotic to optimize butyrate production

73 furosine in milk with oligosaccharides from lactulose as compared to its counterpart without this in

74 ation of breath tests, and those that employ lactulose as the substrate, in particular, to the diagno

75 m an enzymatic process for the production of lactulose at the laboratory scale.

76 m 7 studies, we assembled a database of 1461 lactulose-based tests; in 422 of these tests, satisfacto

77 The lactulose began to decompose above 180 degrees C.

78 pe of excreted gas, a prevalence of abnormal lactulose breath test in 84% of IBS patients, and a 75%

79 al culture of duodenal aspirate, glucose and lactulose breath tests.

80 After lactulose, breath hydrogen was greater on the standard t

81 n of increased rectal gas were reported with lactulose but not with either of the two fiber preparati

82 Lactose was isomerised to lactulose by microwave heating and purified by a methano

83 erein demonstrate that oligosaccharides from lactulose can be used as prebiotic ingredients in a wide

84 A final lactulose concentration of 6.7+/-0.4g/L was determined.

85 des was obtained at 70 degrees C and 60% w/w lactulose concentration, while maximum specific producti

86 -1) was obtained at 70 degrees C and 40% w/w lactulose concentration.

87 fied the whole-gut transit of a radiolabeled lactulose-containing test meal by using gamma scintigrap

88 ctulose-rich product (LRP; approximately 70% lactulose content to total sugar) through crystallizing

89 rocedure to a product with approximately 72% lactulose content.

90 Average lactulose contents from 51 to 1549 mg/L were detected at

91 using the ICT, and subsequent treatment with lactulose could substantially reduce societal costs by p

92 , rhamnose (monosaccharides), sucralose, and lactulose (disaccharides).

93 es, the carbohydrates sucrose, rhamnose, and lactulose do not serve as robust growth substrates in vi

94 Participants consumed 20 g of lactulose during a continuous 10-hour sodium d3-acetate

95 ntensity ultrasound (US) on the formation of lactulose during lactose isomerization and on the obtent

96 e of lactose isomerization, higher values of lactulose, epilactose and galactose being observed in co

97 score) was inversely associated with percent lactulose excreted, a measure of intestinal permeability

98 eltaLAZ) at 12 and 24 wk and percent urinary lactulose excretion (%L) at 12 and 24 wk.

99 in length-for-age z-score ( LAZ) and urinary lactulose excretion (%L) at 12-mo-old.

100 Urine was analyzed for lactulose excretion (%L).

101 vements in EED, as measured by percentage of lactulose excretion (%L). %L <0.2% was considered normal

102 or propranolol to prevent variceal bleeding, lactulose for hepatic encephalopathy, combination aldost

103 ly detection of saccharide biomarkers (i.e., lactulose) for applications related to GI barrier dysfun

104 Regarding the influence of US on lactulose formation, in general, in a buffered system (p

105 All patients received lactulose from 2 days before surgery for 2 weeks.

106 The production of the sugars fructose and lactulose from lactose using the enzymes beta-galactosid

107 bstitutable resources, methylgalactoside and lactulose, generates stabilizing frequency-dependent sel

108 ent in HRQOL: patients receiving crystalline lactulose had an 8.1-point (95% CI: 3.7-12.4) increase c

109 Lactulose had no effect on METH-induced hyperthermia.

110 on the bioactivity of oligosaccharides from lactulose has encouraged us to study their physicochemic

111 administered but non-absorbable disaccharide lactulose have increased densities of intestinal bifidob

112 me continues, the utility and specificity of lactulose hydrogen breath testing is yet again being cal

113 me continues, the utility and specificity of lactulose hydrogen breath testing is yet again questione

114 Lactulose improves sleep and activity impairment in pati

115 , and it allowed quantitation of lactose and lactulose in all samples at a high level of precision an

116 n HPLC-ELSD method for the quantification of lactulose in complex sugar solutions.

117 h rifaximin was slightly more effective than lactulose in the maintenance of remission and decreased

118 andardised diet (weeks 2-9), with added oral lactulose in weeks 6-7.

119 omposed of our isolated A. caccae strain and lactulose increased luminal butyrate in gnotobiotic mice

120 Psyllium has been reported to inhibit lactulose-induced colonic mass movements and to benefit

121 In summary, we have shown that lactulose induces a reversible qualitative and quantitat

122 ed by greater total hydrogen excretion after lactulose ingestion, a correlation between the pattern o

123 Consequent to lactulose ingestion, there was a reduction of plasma FFA

124 ction (measured in breath samples after oral lactulose intake).

125 Lactulose is a non-absorbable disaccharide, which alters

126 Lactulose is a well-known prebiotic and supports the all

127 Lactulose is an established and reasonably effective tre

128 ed for their ability to discriminate between lactulose, l-rhamnose, 3-O-methyl-d-glucose, and xylose.

129 Septic patients had increased lactulose/L-rhamnose urine excretion ratios (0.23 +/- 0.

130 nt with the experimental values for lactose, lactulose, lacto-N-biose, and N-acetyllactosamine, all o

131 as transglycosylation activities on lactose, lactulose, maltose and sucrose substrates.

132 sorbose, and tagatose and the disaccharides lactulose, maltulose, and palatinose.

133 opterin), permeability (alpha-1-antitrypsin, lactulose, mannitol), and repair (regenerating gene 1bet

134 In Bangladesh, higher concentrations of lactulose, mannitol, and alpha-1 antitrypsin were associ

135 bility (GP) were evaluated by measurement of lactulose, mannitol, D-xylose and sucrose respectively i

136 ld length and collected stool and blood; the lactulose-mannitol urine test was also conducted at all

137 was assessed every 6 hours by measuring the lactulose/mannitol (L/M) excretion ratio.

138 PBBV, and pBoB, LDA statistically segregated lactulose/mannitol (L/M) ratios from 0.1 to 0.5, consist

139 testinal barrier function was studied by the lactulose/mannitol absorption test, faecal and serum zon

140 was assessed every 6 hours by measuring the lactulose/mannitol excretion ratio.

141 , and gut integrity as determined by urinary lactulose/mannitol ratio (L:M).

142 nary lactulose and mannitol recovery and the lactulose/mannitol ratio (LMR) were measured, to determi

143 In contrast, the lactulose/mannitol ratio was only doubled in DuP753-trea

144 rs of impaired gut permeability, such as the lactulose/mannitol ratio, plasma endotoxin concentration

145 Intestinal permeability, as assessed by the lactulose/mannitol ratio, showed 6-fold and 12-fold incr

146 For 30 children, performance on the lactulose/mannitol test, a test commonly used to assess

147 ntestinal permeability was measured with the lactulose/mannitol test.

148 MAM children, biomarkers of EED included the lactulose: mannitol (L: M) test, 15 host fecal mRNA tran

149 We examined lactulose:mannitol (Lac:Man) permeability in obese indiv

150 egrity, which can be measured by the urinary lactulose:mannitol excretion test, deteriorates with the

151 ty is the lactulose:mannitol test, where the lactulose:mannitol ratio (LMR) is measured.

152 s averaged from 9 to 15 mo, and averaged the lactulose:mannitol ratio z-score (LMZ) at 9 and 15 mo.

153 y (based on 0-2 h levels of mannitol and the lactulose:mannitol ratio); SB permeability was greater i

154 and gut integrity [assessed by using urinary lactulose:mannitol ratios (LMRs)].

155 gars on measures of intestinal permeability (lactulose:mannitol test, plasma zonulin, and plasma lipo

156 in assessing small bowel permeability is the lactulose:mannitol test, where the lactulose:mannitol ra

157 Mean lactulose:mannitol z-scores during the first 2 y of life

158 binding modes of four galactose derivatives: lactulose, melibionic acid, thiodigalactoside, and m-nit

159 to growth-limiting concentrations of either lactulose, methyl-galactoside, or a 72:28 mixture of the

160 r, a significant increase in transepithelial lactulose movement and neutrophil migration occurred in

161 Neither the transepithelial lactulose movement in the presence of neutrophils from,

162 Ex vivo measurements of lactulose movements across intestinal epithelial monolay

163 The latter suggests that the effect of lactulose on hepatic encephalopathy may not be related t

164 Treatments considered were lactulose or rifaximin, which were assumed to reduce the

165 ), neopterin (NEO), and urinary LR ratio and lactulose percentage recovery.

166 Although a significant change in lactulose permeability from day 1 to day 2 postinjury co

167 not be demonstrated in the B and EF groups, lactulose permeability in the B+EF group on day 2 postin

168 EED was defined by a lactulose permeability test.

169 Lactulose permeability was increased in the injured rat

170 injury group (B+EF) had the highest level of lactulose permeability.

171 test meals were dextrose, dextrose plus 10 g lactulose, plain hot rice, or plain cold rice.

172 Predictors of response to lactulose, probiotics and L-ornithine-L-aspartate therap

173 Predictors of response to lactulose, probiotics, and L-ornithine-L-aspartate thera

174 Lactulose, probiotics, L-ornithine-L-aspartate, and pota

175 Bifidobacteria metabolize lactulose, produce high concentrations of acetate and ac

176 yield and the reaction rate of fructose and lactulose production from lactose.

177 y hydrolysed in the small intestine, whereas lactulose, recognised prebiotic carbohydrate, reaches th

178 Across all studies, lactulose recovery was strongly correlated with recoveri

179 aepithelial lymphocytes were associated with lactulose % recovery (exp.

180 llowing parameters were determined (e.g. for lactulose): recovery (106+/-7%), precision (98%), correc

181 The enzymatic generation of lactulose requires fructose as nucleophilic acceptor.

182 ith HE, 32.4% and 63.3% filled rifaximin and lactulose, respectively.

183 h compared with 1-h urine collections in the lactulose rhamnose (LR) dual sugar test.

184 We set out to correlate recoveries of lactulose, rhamnose, xylose, 3-O-methyl-D-glucose, and t

185 At 90 minutes, a plasma lactulose/rhamnose concentration was also measured, with

186 s. 8.04% +/- 2.55%; p < 0.001) and increased lactulose/rhamnose ratio (2.77 +/- 4.24 vs.1.10 +/- 0.98

187 ility, as assessed by changes in the urinary lactulose/rhamnose ratio (L/R ratio) measured by High Pr

188 e relationship between the (13)C-SBT and the lactulose/rhamnose ratio (LR) and growth in children.

189 ED (n = 26) groups on the basis of a urinary lactulose/rhamnose ratio (LRR) cutoff based on mean + 2

190 The lactulose/rhamnose ratio was greater in feed-intolerant

191 amnose concentration was also measured, with lactulose/rhamnose ratio, a marker of small intestinal m

192 degrees C, and gut permeability (5-h urinary lactulose:rhamnose ratios) increased 3-fold after exerci

193 mnose, xylose, 3-O-methyl-D-glucose, and the lactulose:rhamnose recovery ratio (LRR), and where possi

194 ized permeate was subsequently purified to a lactulose-rich product (LRP; approximately 70% lactulose

195 Afterwards, lactose and the lactulose-rich product (PLu) were conjugated with either

196 Twenty subjects on lactulose/rifaximin were randomized 1:1.

197 to mannitol (L:M) and of urinary sucrose to lactulose (S:L) excretion.

198 The lactulose showed crystalline behaviour that was differen

199 Considering these conditions, lactulose showed high resistance to intestinal digestion

200 th that after the nonabsorbable disaccharide lactulose suggested that the tea extract induced malabso

201 ted a 28-day randomized trial of crystalline lactulose therapy (20 g BID) compared with no HE-directe

202 of remission from OHE; however, compared to lactulose therapy in CHE, it is not cost-effective.

203 Predictors of response to lactulose therapy in hepatic encephalopathy have been re

204 Many clinicians initiate lactulose therapy to address poor PROs.

205 Lactulose therapy was effective for cirrhotic patients a

206 re than 90% of patients received concomitant lactulose therapy.

207 d colonic transit after consumption of 20 mL lactulose three times daily with or without 3.5 g psylli

208 primary outcomes were the ratios of urinary lactulose to mannitol (L:M) and of urinary sucrose to la

209 most commonly used test has been the urinary lactulose to mannitol ratio (L:M), which primarily asses

210 es to Cryptosporidium and rotavirus, and the lactulose to mannitol ratio for intestinal permeability

211 Intestinal Permeability (PI) index (Lactulose to Mannitol ratio) was significantly reduced (

212 sured by the urinary fractional excretion of lactulose-to-mannitol ratio (LMR) at recruitment in 1420

213 ed using the urinary fractional excretion of lactulose-to-mannitol ratio (LMR).

214 risk scores, urinary fractional excretion of lactulose-to-mannitol ratio, fecal calprotectin (FCP), a

215 ith baseline CD-polygenic risk scores or the lactulose-to-mannitol ratio.

216 The d-xylose test and lactulose-to-rhamnose ratio were used to test for possib

217 tated diffusion and paracellularly (based on lactulose transport) via glucose-activated solution drag

218 c administration for systemic infections and lactulose treatment for hepatic encephalopathy, can impa

219 composition changed before, during and after lactulose treatment in a large animal model.

220 ed to excitotoxicity, the effect of METH and lactulose treatment on calpain-mediated spectrin proteol

221 oducts, and this increase was prevented with lactulose treatment.

222 Disease (MELD) score, serum sodium, albumin, lactulose use, rifaximin use, and benzodiazepine/barbitu

223 Lactulose users reported more good sleep (92% vs. 52%, p

224 of rosiglitazone therapy and treatment with lactulose, vitamin K, fresh frozen plasma, ventilatory a

225 Lactulose was associated with a significantly ( p = 0.00

226 In meta-analyses of randomized trials, lactulose was associated with reduced mortality relative

227 ion yielding a theoretical maximal amount of lactulose was determined as 1.28 or 0.74 mol/kg fructose

228 and nutrition arms (0.23-0.27 log ng/mL) and lactulose was higher in the WSH arm (0.30 log mmol/L; 95

229 omposition on the concentration of generated lactulose was investigated.

230 s of fructosyl-galacto-oligosaccharides from lactulose was performed with commercial beta-galactosida

231 Diagnosis with ICT and lactulose was the most cost-effective approach (cost/MVA

232 extracellular glutamate after METH exposure, lactulose was used to decrease plasma and brain ammonia.

233 g enriched C-sucrose, 1.1 g rhamnose, 7.5 mL lactulose) was administered into the small intestine.

234 operties of juice with oligosaccharides from lactulose were acceptable and similar to those of apple

235 All four strategies with lactulose were cost-saving compared with the status quo.

236 Acarbose and lactulose were used to examine the disaccharidase-relate

237 ) and quantification (LOQ) were achieved for lactulose with 4,7-o-PBBV (LOD 41 muM, LOQ 72 muM).

238 -WbsJ has a higher affinity for lactose than lactulose with apparent Km values of 7.81 mM and 13.26 m

239 es provide good sensitivity for disaccharide lactulose with low micromolar detection and quantificati

240 omeric region of saccharide configuration of lactulose with WPH.

241 6-well format to enable sensitive testing of lactulose within a broad range of concentrations.